Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Opus Genetics, Inc. reported second quarter ended June 30, 2023 results: revenue approximately $40.0 million, net income Net loss for the three and six months e.
- Period
- second quarter ended June 30, 2023
- Revenue
- approximately $40.0 million
- Net income
- Net loss for the three and six months e
- Result
- reported results
Exact text from the filing
Results for Second Quarter 2023 and Provides Corporate Update End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR) Cash Balance of $40 Million Expected to Fund Operations into 2025 Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire Common Share Purchase Agreement
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Opus Genetics, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $50,000,000 (effective 2023-08-10).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Lincoln Park Capital Fund, LLC
- Value
- up to $50,000,000
- Effective
- 2023-08-10
Exact text from the filing
On August 10, 2023, Ocuphire Pharma, Inc. (the “Company”) entered into a common stock purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right, but not the obligation, to sell to Lincoln Park up to $50,000,000 of shares of the Company’s common stock (the “Purchase Shares”) from time to time over the 30-month term of the Purchase Agreement.
View on SEC.gov